2013 Press Releases

Webcast ImageWebcast
MannKind 8/11/14 Conference Call (Replay)
08/11/14 at 8:30 a.m. ET
Webcast ImageWebcast
Q2 2014 MannKind Earnings Conference Call (Replay)
08/11/14 at 2:00 p.m. PT
Receive E-mail AlertsEmail Alerts
Sign up to receive e-mail alerts whenever MannKind has a news release. Just enter your e-mail address and click submit.
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
11/27/13MannKind Corporation to Present at The Piper Jaffray 25th Annual Healthcare Conference
VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 27, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at The Piper Jaffray 25th Annual Healthcare Conference on Wednesday, December 4, 2013 at 10:00 AM (ET) at The New York Palace, New York, New York. Interested parties can access a link to the live webcast of the presentations from the News... 
Printer Friendly Version
11/07/13MannKind Corporation to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum
VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 7, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 14, 2013 at 11:30 AM (ET) at the Westin Grand Central in New York City. Interested parties can access a link to the live webcast of the presentatio... 
Printer Friendly Version
11/04/13MannKind Corporation Reports 2013 Third Quarter Financial Results
- Conference Call to Begin Today at 5:00 PM ET - VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 4, 2013-- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the third quarter ended September 30, 2013. For the third quarter of 2013, total operating expenses were $44.8 million, compared to $35.5 million for the third quarter of 2012, an increase of $9.3 million. Research and development (R&D) expenses were $27.3 million... 
Printer Friendly Version
10/30/13MannKind Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA
VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 30, 2013-- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for AFREZZA® (insulin human [rDNA origin]) Inhalation Powder. The FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011 and assigned a user fee goal date of April 15, 2014. ... 
Printer Friendly Version
10/28/13MannKind Corporation to Hold 2013 Third Quarter Financial Results Conference Call on November 4, 2013
VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- MannKind Corporation (Nasdaq: MNKD) will release its 2013 third quarter financial results on Monday, November 4, 2013 and its management will host a conference call to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 4, 2013. To participate in the live call by telephone, please dial (800) 447-0521 or (847) 413-3238 and use the... 
Printer Friendly Version
10/14/13MannKind Resubmits New Drug Application to U.S. FDA for AFREZZA for the Treatment of Adults with Diabetes
VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 14, 2013-- MannKind Corporation (Nasdaq: MNKD) today announced the resubmission on October 13, 2013 of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder with an indication to improve glycemic control in adults with type 1 or type 2 diabetes. The resubmission is based on the entire... 
Printer Friendly Version
09/03/13MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
VALENCIA, Calif.--(BUSINESS WIRE)--Sep. 3, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 3:30 PM (ET) at the Grand Hyatt Hotel in New York City. Interested parties can access a link to the live webcast of the presentations from the News & ... 
Printer Friendly Version
08/16/13MannKind Satisfies Conditions for Second Tranche of Convertible Note Financing
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 16, 2013-- MannKind Corporation (Nasdaq: MNKD) today announced that, pursuant to a Facility Agreement (the “Facility Agreement”) dated July 1, 2013 between Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and MannKind, the conditions that obligate Deerfield to purchase the second $40 million tranche of 9.75% senior secured convertible notes (the ... 
Printer Friendly Version
08/14/13CORRECTING and REPLACING MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 14, 2013-- Second graph under Other Results subhead, second sentence should read: The event rate of severe hypoglycemia was also lower in the AFREZZA-Gen2 group (8.05 events per 100 subject-months) than in the insulin aspart group (14.45 events per 100 subject-months); however, this difference was not statistically significant (p=0.1022) (sted The event rate of severe hypoglycemia was also lower in the AFREZZA-Gen2... 
Printer Friendly Version
08/14/13MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 14, 2013-- MannKind Corporation (Nasdaq: MNKD) today announced positive preliminary results from Study 171, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind’s next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler), in patients with type 1 diabetes. Highlight... 
Printer Friendly Version
08/14/13MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 14, 2013-- MannKind Corporation (Nasdaq: MNKD) today announced positive preliminary results from Study 175, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy administered using MannKind’s next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler), in patients with type 2 diabetes. Highlights... 
Printer Friendly Version
08/14/13MannKind Announces Positive Clinical Data for AFREZZA; Both AFFINITY Phase 3 Studies Meet Primary Endpoints
Conference Call to be held at 4:00 pm (EDT) today VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 14, 2013-- MannKind Corporation (Nasdaq:MNKD) today announced that it will hold a conference call at 4:00 pm (EDT) today to discuss preliminary results from Study 171 and Study 175, two Phase 3 clinical studies of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy administered using Ma... 
Printer Friendly Version
08/09/13MannKind Corporation Reports 2013 Second Quarter Financial Results
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 9, 2013-- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2013. For the second quarter of 2013, total operating expenses were $41.6 million, compared to $44.1 million for the second quarter of 2012, a decrease of $2.5 million. Research and development (R&D) expenses were $27.1 million for the second quarter of 2013 compared to $26.6 million ... 
Printer Friendly Version
07/03/13MannKind Corporation to Present at 8th Annual JMP Securities Healthcare Conference
VALENCIA, Calif.--(BUSINESS WIRE)--Jul. 3, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the 8th Annual JMP Securities Healthcare Conference on Wednesday, July 10, 2013 at 11:00 AM (ET) at The St. Regis Hotel in New York. Interested parties can access a link to the live webcast of the presentations from the News & Event... 
Printer Friendly Version
07/01/13MannKind Announces $160 Million Debt Financing
VALENCIA, Calif.--(BUSINESS WIRE)--Jul. 1, 2013-- MannKind Corporation (Nasdaq:MNKD) announced today that it has entered into a secured financing with affiliates of Deerfield Management Company L.P. (“Deerfield”), who have committed to purchase up to $160 million in senior secured notes. Under the terms of the financing, Deerfield committed to provide up to four tranches of $40 million each on the following schedule: at closing; following ... 
Printer Friendly Version
06/17/13MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes
VALENCIA, Calif.--(BUSINESS WIRE)--Jun. 17, 2013-- MannKind Corporation (Nasdaq: MNKD) today announced that all follow-up visits have been completed for the patients enrolled in Study 175, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) inhalation powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind’s next-generation inhaler. MannKind expects to release data from this study later this ... 
Printer Friendly Version
06/11/13MannKind to Present at Wells Fargo Securities Research & Economics 2013 Healthcare Conference
VALENCIA, Calif.--(BUSINESS WIRE)--Jun. 11, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Wells Fargo Securities Research & Economics 2013 Healthcare Conference on Tuesday, June 18, 2013 at 2:55 PM (ET) at the InterContinental Hotel in Boston. Interested parties can access a link to the live webcast of the presentat... 
Printer Friendly Version
05/31/13MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes
VALENCIA, Calif.--(BUSINESS WIRE)--May. 31, 2013-- MannKind Corporation (Nasdaq: MNKD) today announced that all follow-up visits have been completed for the patients enrolled in Study 171, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) inhalation powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind’s next-generation inhaler. MannKind expects to release data from this study later this ... 
Printer Friendly Version
05/29/13MannKind to Present at Jefferies 2013 Global Healthcare Conference
VALENCIA, Calif.--(BUSINESS WIRE)--May. 29, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5, 2013 at 11:00 a.m. (ET) in New York. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's websi... 
Printer Friendly Version
05/09/13MannKind Corporation Reports 2013 First Quarter Financial Results
- Conference Call to Begin Today at 5:00 P.M. EDT - VALENCIA, Calif.--(BUSINESS WIRE)--May. 9, 2013-- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, total operating expenses were $36.4 million, compared to $33.9 million for the first quarter of 2012, an increase of $2.5 million. Research and development (R&D) expenses were $26.4 million... 
Printer Friendly Version
05/08/13MannKind to Present at Bank of America Merrill Lynch 2013 Health Care Conference
VALENCIA, Calif.--(BUSINESS WIRE)--May. 8, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 1:40 pm Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada. Interested parties can access a link to the live webcast of the prese... 
Printer Friendly Version
05/02/13MannKind Corporation to Hold 2013 First Quarter Financial Results Conference Call on May 9, 2013
VALENCIA, Calif.--(BUSINESS WIRE)--May. 2, 2013-- MannKind Corporation (Nasdaq: MNKD) will release its 2013 first quarter financial results on Thursday, May 9, 2013 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2013. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief ... 
Printer Friendly Version
02/26/13MannKind Corporation to Present at the Cowen and Company 33rd Annual Health Care Conference
VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 26, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Cowen and Company 33rd Annual Health Care Conference on March 5, 2013 at 10:40 AM (EST) at the Boston Marriott Copley in Boston, Massachusetts. Interested parties can access a link to the live webcast of the presenta... 
Printer Friendly Version
02/11/13MannKind Corporation Reports 2012 Fourth Quarter and Full Year Financial Results
- Conference Call to Begin Today at 5:00 PM ET - VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 11, 2013-- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and year ended December 31, 2012. For the fourth quarter of 2012, total operating expenses were $33.5 million, compared to $30.6 million for the same quarter of 2011, an increase of $2.9 million. Research and development (R&D) expenses were ... 
Printer Friendly Version
02/04/13MannKind Corporation to Hold 2012 Fourth Quarter and Full Year Financial Results Conference Call on February 11, 2013
VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 4, 2013-- MannKind Corporation (Nasdaq: MNKD) will release its 2012 fourth quarter and full year financial results on Monday, February 11, 2013 and its management will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM (Eastern Time) on February 11, 2013. Presenting from the Company will be its Chairman and Chief Executive ... 
Printer Friendly Version
01/03/13MannKind Corporation to Present at The 31st Annual J.P. Morgan Healthcare Conference
VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 3, 2013-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at The 31st Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2013 at 8:00 AM (PST) at St. Francis Hotel in San Francisco, California. Interested parties can access a link to the live webcast of the presentat... 
Printer Friendly Version


Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet